The role of B cells in autoimmune diseases involves different cellular functions, including the
well‐established secretion of autoantibodies, autoantigen presentation and ensuing …

Autoimmune diseases are characterized by the recognition of self‐antigens by the immune
system, which leads to inflammation and tissue damage. B cells are directly and indirectly …

Purpose of review FDA-approved B cell-targeted therapy has expanded to a multitude of
autoimmune diseases ranging from organ specific diseases, like pemphigus and multiple …

Selective B-cell depletion with anti-CD20 therapy is a promising novel treatment option for
patients with refractory autoimmune disease. The anti-CD20 antibody, rituximab, is the first …

The advent of therapies that specifically target the B‐lymphocyte lineage in human disease
has rejuvenated interest in the mechanistic biology by which B cells mediate autoimmunity …

Autoimmunity results from abnormal B‐and T‐cell recognition of self‐antigens, which leads
to autoantibody production in many cases. Autoantibodies produced by B‐cell‐derived …

B lymphocytes contribute to immunity through organogenesis of secondary lymphoid
organs, presentation of antigen to T cells, production of antibodies, and secretion of …

The pathogenic roles of B cells in human autoimmune diseases involve a multitude of
mechanistic pathways and include the well-established contributions of autoantibodies and …

B cell-directed therapies are promising treatments for autoimmune disorders. Besides
targeting CD20, newer B cell-directed therapies are in development that target other B cell …

The pathogenic roles of B cells in autoimmune diseases occur through several mechanistic
pathways that include autoantibodies, immune complexes, dendritic and T cell activation …